Preventing Bleeds by Treatment: New era for hemophilia
In the Vice President Medical’s plenary of the WFH 2016 World Congress, Marijke van den Berg, discusses how bleeds may be prevented by treatment in a new era for hemophilia which she qualifies as exciting times.
Online CFC Registry
Hemostatic Agents
This eLearning module presents Section 4 of the WFH Guidelines for the Management of Hemophilia: Hemostatic Agents. Detailed illustrations, interactive features, a glossary, supplementary resources and self-quizzes bring to life the WFH recommendations regarding FVIII and FIX clotting factor concentrates, fresh frozen plasma, cryoprecipitate, and other pharmacological options including DDAVP, tranexamic acid, and epsilon aminocaproic […]
Desmopressin (DDAVP)
This resource has also been translated into the following languages, with permission from the WFH, by NMOs: Polish Desmopressin (DDAVP) may be the treatment of choice for patients with mild or moderate hemophilia A and type 1 von Willebrand disease (VWD). This Fact Sheet presents essential information about this synthetic medicine which costs much less than […]
New Developments in Treatment for Bleeding Disorders – Novel Therapies
New panel discussion: New Developments in Treatment for Bleeding Disorders – Novel Therapies, is a cure for hemophilia around the corner? While clotting factor concentrates remain, by far, the mainstay of the management of hemophilia, a number of novel therapies under development have the potential to dramatically change the treatment landscape. Leading hematologists and patient […]
Expanding Access to Hemophilia Treatment Products
New panel discussion: Expanding Access to Hemophilia Treatment Products, what will be the game changer? While the WFH vision is “Treatment for All,” the majority of the world’s population has little to no access to hemophilia care. Patient advocates and WFH Humanitarian Aid and Public Policy representatives debate what might be the game changer in […]
Online CFC Registry
[cjtoolbox name=’Kendo-CFC’]
Desmopressin (DDAVP) – Polish
Also Available In: English, Spanish, French, Arabic, Russian, Simplified Chinese This is not an official WFH translation. This resource has been translated with permission by a WFH National Member Organization (NMO), and is shared here with their kind permission. Translating organizations are encouraged to have translations reviewed by local experts, the WFH is not responsible for […]
Proceedings of the WFH’s Ninth WFH Global Forum on Research and Treatment Products for Bleeding Disorders
A summary of discussions held at the Ninth WFH Global Forum on Research and Treatment Products for Bleeding Disorders which brings together patient groups, healthcare providers, researchers, regulators, industry representatives, and not-for-profit fractionators.
Guide to National Tenders for the Purchase of Clotting Factor Concentrates
This guide explains how a national procurement system of factor concentrates can help to ensure that people with bleeding disorders have access to treatment which is not only sufficient in quantity, but also meets the required standards in relation to safety, efficacy, and quality. The second edition includes diverse case studies, discussion of prolonged half-life […]
Proceedings of the WFH’s Eighth Global Forum on the Safety and Supply of Treatment Products for Bleeding Disorders
A summary of discussions held at the World Federation of Hemophilia’s Global Forum on the Safety and Supply of Hemophilia Treatment Products, which brings together patient groups, healthcare providers, regulators, industry representatives, and not-for-profit fractionators.
Fibrinolytic Inhibitors in the Management of Bleeding Disorders
A description of the mechanism of action of fibrinolytic inhibitors and their use in the treatment of inherited bleeding disorders including hemophilia A and B, von Willebrand disease, and platelet disorders.